Advertisement
20th Annual Piper Jaffray Health Care Conference
Transition will present at the upcoming 20th Annual Piper Jaffray Health Care Conference. The presentation will take place on Tuesday, December 2nd, 2008 at 12:30 P.M. (Eastern Time) at the New York Palace.
Advertisement
2008 Annual General Meeting of Shareholders
Transition's Annual General Meeting will occur Monday, December 8, 2008 at the MaRS Centre, South Tower, 101 College Street, Main Floor, Room CR-3, Toronto, Ontario at 4:00 P.M. (Eastern Time).
2008 Healthcare Conference hosted by RBC Capital Markets
Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition, will participate in the upcoming 2008 Healthcare Conference hosted by RBC Capital Markets. Dr. Cruz is scheduled to participate in a panel session titled "The Challenge of Alzheimer's Disease" on Thursday, December 11th, 2008 between 12:30 - 1:25 P.M. (Eastern Time) at the Westin Times Square New York. A live webcast and archived version of this event will be available on the Transition website www.transitiontherapeutics.com.
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.
About Transition ----------------
SOURCE Transition Therapeutics Inc.
